AstraZeneca Continues Pipeline Expansion Via Two Licensing Deals Totaling $800 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
Agreements expand the firm’s position in the COPD space, while also entering obesity, diabetes and metabolic syndrome space.
You may also be interested in...
AstraZeneca Hits Anti-Infective Target With Arrow Acquisition
Acquisition of U.K. biotech reflects AstraZeneca's core therapeutic focus in infection, the company says.
AstraZeneca Hits Anti-Infective Target With Arrow Acquisition
Acquisition of U.K. biotech reflects AstraZeneca's core therapeutic focus in infection, the company says.
Acomplia User Fee Date For Weight Loss Is April 26
Sanofi-Aventis has not determined a timetable for responding to FDA’s “not approvable” letter for a smoking cessation claim.